An Economic Evaluation of Voriconazole versus Amphotericin B for the Treatment of Invasive Aspergillosis in Canada | Zendy

Coleman Rotstein | Zendy; Michél Laverdière | Zendy; Anne Marciniak | Zendy; Farzad Ali | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

An Economic Evaluation of Voriconazole versus Amphotericin B for the Treatment of Invasive Aspergillosis in Canada

Author(s) -

Coleman Rotstein,

Michél Laverdière,

Anne Marciniak,

Farzad Ali

Publication year - 2004

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 38

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2004/183087

Subject(s) - voriconazole , aspergillosis , amphotericin b , medicine , intensive care medicine , antifungal , immunology , dermatology

Invasive aspergillosis (IA) is a serious fungal infection that affects immunocompromised patients. The Global Comparative Aspergillosis study demonstrated that voriconazole, a new broad-spectrum triazole, had better responses and improved survival compared with conventional amphotericin B deoxycholate (CAB) and other licensed antifungal therapy (OLAT) for the treatment of definite or probable aspergillosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research